Latest News and Press Releases

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR...

Leuven, BELGIUM, 22 January 2024 9:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announced today its new corporate strategy to further...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special...

Regulated Information Leuven, BELGIUM – January 17, 2024 – 7:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to...

Regulated Information Leuven, BELGIUM – January 12, 2024 – 8:00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to...

  Regulated information – Inside information No bankruptcy filing Significant reduction in Working Capital costsAtlas commits to fund Oxurion’s Working Capital costs (including the Preclinical GA...

Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...

  Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has Decided to Take Necessary Steps to File for...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special...

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...